Exploring Hormone Replacement Therapy for Females: A Comprehensive Guide

In the UK, a clinically proven testosterone therapy called Androfeme, specifically designed for women, is currently only available privately. This therapy has been found to be safe and well-tolerated by women, with no long-term or irreversible side effects when appropriately dosed.

For women seeking testosterone therapy, private doctors may prescribe it for low energy and mood, providing they are willing to trial the treatment. It's important to note that in the NHS, a low libido or HSDD (hypo-active sexual desire disorder) is the only approved symptom for prescribing testosterone therapy during menopause.

Testosterone therapy can significantly help alleviate symptoms of menopause and perimenopause, such as a flagging libido. Additionally, it can improve brain fog, lack of energy and strength, hair growth, lessen vaginal dryness and discomfort, and aid in weight management.

Two brands of testosterone available on the NHS for women with low libido are Testogel and Tostran. For those already on HRT and experiencing a loss of sex drive, testosterone can be obtained from the NHS.

In the private sector, more options exist. Private menopause specialists may prescribe testosterone for reasons other than a flagging sex drive, if the circumstances are right. Bespoke or 'compounded' testosterone creams are also available privately.

One exciting development is the TEPI patch, which, once approved, would offer women more choices and advance the discussion about female testosterone. However, the availability of the TEPI testosterone patch is not yet confirmed, as it is still undergoing trials and awaiting regulatory approval.

Regular monitoring via venous blood tests is crucial when on testosterone therapy, but it can be challenging to obtain from the NHS. Fingerprick tests for testosterone levels are available online and from pharmacies like Superdrug, but their validity and methodology are questionable.

Celebrities like Kate Winslet and Gabby Logan are prominent figures advocating for testosterone therapy during menopause, raising awareness and encouraging open discussions about this treatment option. Dr Barton, a prominent figure in the field, expresses enthusiasm about the TEPI patch, believing it will provide women with more choices and propel the conversation about female testosterone therapy forward.

In conclusion, testosterone therapy is an emerging option for women in the UK seeking to manage symptoms of menopause and perimenopause. While it is primarily available privately at present, the introduction of the TEPI patch could bring this treatment into the NHS in the future, offering more choices and advancing the conversation about female testosterone therapy.